Drug Discovery World

AUGUST 11, 2023

GenScript Biotech and T-MAXIMUM Biotech have formed a strategic collaboration to develop T-MAXIMUM’s CAR-T cell therapy using GenScript’s CRISPR nucleic acid reagents. GenScript will provide various CRISPR reagents to support the development of the universal CAR-T products from discovery to commercialisation.

Reagent 52

Reagent Development Gene Editing Production 52

The Pharma Data

OCTOBER 27, 2020

“The MassARRAY SARS-CoV-2 Panel is the only assay on the market with 5 viral genome targets multiplexed into a single reaction, making it robust against potential mutations arising in the viral genome,” said Dr. Darryl Irwin , Vice President of Scientific Affairs. ” More information is available at www.agenabio.com.

Genetic Analysis 52

Genetic Analysis Genome Genomics Reagent 52

Roots Analysis

AUGUST 28, 2022

Currently, several stakeholders are engaged in offering integrated solutions (platforms, software applications, services) to perform tissue analysis and spatial phenotyping, across the full continuum from discovery through translational and clinical research. Likely Growth of the Spatial Omics Solutions Market.

Genome 52

Genome Genomics RNA Genome Project 52

pharmaphorum

DECEMBER 16, 2022

Clinical trials technology company Saama has hired Dr Clinton White as its new chief delivery officer. Drawing on 25 years in clinical research, White will oversee Saama’s project delivery teams. Pharmaceutical supplier PBSC has tapped Jose Ruiz as the new president and general manager for its US office.

Behavioural Health 52

Behavioural Health Reagent Gene Therapy Production 52

XTalks

AUGUST 18, 2020

The study was funded by a clinical research agreement with the NBA and the players’ union – the National Basketball Players Association (NDG) – which together, contributed over $500,000 to fund the Yale study. The results of the two tests displayed almost universal equivalency.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

The Pharma Data

DECEMBER 23, 2020

Marketing Authorization was based on the pivotal phase III ATLAS (Antiretroviral Therapy as Long-Acting Suppression), FLAIR (First Long-Acting Injectable Regimen) and ATLAS-2M studies. Astrea is a leading provider of affinity separation solutions to the pharmaceutical and biomanufacturing industries. It is a division of Gamma Biosciences.

Drugs 52

Drugs Licensing Licensing Vaccination 52

The Pharma Data

OCTOBER 14, 2020

The new services have been developed to support pre-clinical research by optimizing hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models. The funds will be used to bring Ori’s innovative manufacturing platform to the market.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52